Oxis International, Inc., develops innovative drugs focused on the treatment of cancer and other unmet medical needs. The companies leading drug candidates, OXS-1550, OXS-4235, and OXS-2175 address relapsed/refractory B-cell lymphoma and leukemia, multiple myeloma and associated osteolytic lesions, and triple-negative breast cancer (TNBC). The company is publicly traded on NASDAQ as OXIS.